A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson’s Disease (PASADENA): Rationale, Design and Baseline Data
Frontiers in Neurology（2021）
关键词
Parkinson's disease,alpha-synuclein (alpha-syn),prasinezumab,monoclonal antibodies,disease progression,MDS-UPDRS = Movement Disorder Society-Unified Parkinson's Disease Rating Scale,Phase II clinical trial,disease modification treatments
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要